Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 285 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parasitic Diseases Clear all
Completed Phase 1 Interventional

A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients

NCT00000973
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Pyrimethamine, Leucovorin calcium, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 25, 2026, 7:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Evaluation of the Click Sexual Health Test for the Detection of Neisseria Gonorrhoeae (NG), Trichomonas Vaginalis (TV), and Chlamydia Trachomatis (CT) in Women

NCT04098900
View directory record Official record
Conditions
Chlamydial Infection, Gonococcal Infection, Trichomoniasis
Interventions
Click Sexual Health Test
Diagnostic Test
Lead sponsor
Visby Medical
Industry
Eligibility
14 Years to 99 Years · Female only
Enrollment
309 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Saint Paul, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

NCT00697892
View directory record Official record
Conditions
HIV Infections, Malaria
Interventions
lopinavir/ritonavir, efavirenz, artemether/lumefantrine
Drug
Lead sponsor
Fran Aweeka
Other
Eligibility
21 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection

NCT00120081
View directory record Official record
Conditions
Hookworm Infection
Interventions
Na-ASP-2/Alhydrogel Hookworm Vaccine, Saline placebo
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT06069544
View directory record Official record
Conditions
Malaria
Interventions
BNT165c, BNT165d, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria

NCT00870987
View directory record Official record
Conditions
Malaria
Interventions
DNA vaccine prime, adenovirus type 5 vaccine boost
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects

NCT01068158
View directory record Official record
Conditions
Head Lice
Interventions
0.5% Ivermectin Cream, Placebo control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
5 Months and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
7
States / cities
Little Rock, Arkansas • Delray Beach, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Malaria Challenge With NF54 Strain

NCT00744133
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
NF54 P. falciparum isolate
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 25, 2026, 7:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research

NCT00277849
View directory record Official record
Conditions
Hemoglobin Mutations, Erythrocyte Variants
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Not applicable Interventional

A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS

NCT00002278
View directory record Official record
Conditions
Cryptosporidiosis, HIV Infections
Interventions
Diclazuril
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America

NCT00312663
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Falciparum Malaria Protein 11 with AS01B adjuvant.
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 2 Interventional

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

NCT00000794
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Sulfadiazine, Clarithromycin, Atovaquone, Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
16
States / cities
Los Angeles, California • Miami, Florida • Honolulu, Hawaii + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria

NCT00295581
View directory record Official record
Conditions
Plasmodium Falciparum, Plasmodium Vivax Malaria
Interventions
PpPfs25/ISA51 & ScPvs25/ISA51
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development of a Skin Test for the Na-ASP-2 Hookworm Antigen

NCT00603889
View directory record Official record
Conditions
Hookworm Infection, Allergy
Interventions
Na-ASP-2 Skin Test Reagent
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis

NCT03935217
View directory record Official record
Conditions
Trichomonas Infection
Interventions
Secnidazole, Placebo
Drug
Lead sponsor
Lupin Research Inc
Industry
Eligibility
12 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Birmingham, Alabama • North Miami, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

NCT02485717
View directory record Official record
Conditions
Scabies
Interventions
spinosad topical suspension, 0.9%, Placebo
Drug · Other
Lead sponsor
ParaPRO LLC
Industry
Eligibility
4 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Elk Grove, California • Kissimmee, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protecting Our Future Generation: Promotion of Protective Sexual Health Practices Among Native American Youth and Young Adults Through an Assets-based Self-care Intervention

NCT03895320
View directory record Official record
Conditions
Sexual Behavior, Unprotected Sex, Gonorrhea, Chlamydia, Trichomonas, Sexually Transmitted Diseases, Adolescent Behavior, Self Evaluation
Interventions
Sexual Health Risk Assessment, Sexual Health Score, Sexual Health Messaging, Water SSB Quiz, Water SSB Score, Water SSB Messaging, STI Screening
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
14 Years to 26 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 1 Interventional

Experimental Vaccine for Malaria

NCT00114010
View directory record Official record
Conditions
Malaria
Interventions
AMA1/Alhydrogel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial

NCT00455494
View directory record Official record
Conditions
Malaria
Interventions
AQ-13
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
21 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed Conditions

NCT01591889
View directory record Official record
Conditions
Trichomoniasis
Interventions
Tinidazole
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Weekly Dosing of Malarone ® for Prevention of Malaria

NCT00984256
View directory record Official record
Conditions
Malaria
Interventions
Atovaquone Proguanil, Procedure - malaria challenge
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

NCT03162614
View directory record Official record
Conditions
Malaria
Interventions
RTS,S/AS01E, RTS,S/AS01B, Sporozoite-infected mosquitoes challenge.
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 25, 2026, 7:04 AM EDT
Recruiting No phase listed Observational

Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection

NCT00001645
View directory record Official record
Conditions
Malaria, Intestinal Worms, GI Protozoa, Echiniococcus, Strongyloides
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 7:04 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

NCT02509481
View directory record Official record
Conditions
Malaria, Lymphatic Filariasis
Interventions
Ivermectin, Albendazole
Drug
Lead sponsor
Colorado State University
Other
Eligibility
Not listed
Enrollment
2,712 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 25, 2026, 7:04 AM EDT